Product Description
Mechanisms of Action: CD4 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biotest AG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Tregalizumab](https://pryzm-maps.s3.us-west-2.amazonaws.com/40current_maps.png)
Countries in Clinic: Germany
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Asthma, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Inflammation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Tregulaire | P2 |
Completed |
Environmental Hypersensitivity|Inflammation|Dust mite Hypersensitivity|Asthma, Allergic |
2022-01-12 |
35% |
Tregulaire | P2 |
Completed |
Dust mite Hypersensitivity|Asthma, Allergic|Environmental Hypersensitivity |
2022-01-12 |